TRINETRA › Sectors › Healthcare
Emcure Pharmaceuticals Limited (EMCURE) — share price, P/E and fundamentals
Emcure Pharmaceuticals Limited (NSE: EMCURE) closed at ₹1,866.00 on 30 Oct 2026, +38.5% over one year, against a 52-week range of ₹1,306.50 – ₹2,100.70.
In the quarter ended 30 Jun 2026 (consolidated, filed 6 Aug 2026) it reported revenue of ₹2,580 cr and net profit of ₹294 cr, a 11.4% net margin; revenue grew 22.8% and profit grew 35.3% year on year.
On four consecutive filed quarters its trailing P/E is 35.0; since 22 May 2025 its own P/E has ranged from 30.8 to 43.1 (median 36.8), and today's reading is higher than 25% of those 356 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 23.8%, ROCE 29.8%, debt-to-equity 0.24, Piotroski F-score 6 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 35% of 63 sector peers; PBT margin higher than 33% of 63 sector peers; ROE higher than 84% of 63 sector peers.
Key figures
| Last close | ₹1,866.00 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -4.4% / +14.0% / +38.5% |
| 52-week low – high | ₹1,306.50 – ₹2,100.70 |
| Market capitalisation | ₹35,395 cr |
| Trailing P/E | 35.0 |
| Price / book | 7.15 |
| EV / EBITDA | 18.6 |
| Earnings yield | 2.9% |
| TTM EPS | ₹53.32 |
| TTM net profit | ₹1,011 cr |
| Quarter revenue | ₹2,580 cr |
| Quarter net profit | ₹294 cr |
| Net margin | 11.4% |
| Revenue growth (YoY) | +22.8% |
| Profit growth (YoY) | +35.3% |
| Return on equity | 23.8% |
| ROCE | 29.8% |
| Debt / equity | 0.24 |
| Current ratio | 1.46 |
| Free cash flow | ₹583 cr |
| Piotroski F-score | 6 / 9 |
| Average daily turnover (50 days) | ₹19.4 cr |
Against Healthcare peers
| Metric | EMCURE | Peer median | Percentile |
|---|---|---|---|
| Net margin | 11.39 | 12.89 | 35 |
| PBT margin | 15.25 | 17.68 | 33 |
| ROE | 23.76 | 13.86 | 84 |
| ROCE | 29.83 | 16.59 | 84 |
| Debt / equity | 0.24 | 0.11 | 64 |
| Cash conversion | 1.00 | 1.25 | 32 |
| Trailing P/E | 35.00 | 43.26 | 31 |
| P/B | 7.15 | 5.88 | 62 |
Questions
What is the P/E ratio of Emcure Pharmaceuticals Limited?
Emcure Pharmaceuticals Limited's trailing P/E is 35.0, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 22 May 2025 its P/E has ranged 30.8–43.1.
What were Emcure Pharmaceuticals Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Emcure Pharmaceuticals Limited reported revenue of ₹2,580 cr and net profit of ₹294 cr (consolidated), filed with the exchange on 6 Aug 2026.
What is Emcure Pharmaceuticals Limited's ROE?
Return on equity is 23.8% based on the balance sheet dated 31 Mar 2026.
Does Emcure Pharmaceuticals Limited have debt?
Debt-to-equity is 0.24 on the balance sheet dated 31 Mar 2026.
What is EMCURE's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, EMCURE traded between ₹1,306.50 and ₹2,100.70.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.